Molecular Imaging and Biology

, Volume 17, Issue 4, pp 521–528 | Cite as

Perturbed Development of Striatal Dopamine Transporters in Fatty Versus Lean Zucker Rats: a Follow-up Small Animal PET Study

  • Paul Cumming
  • Simone Maschauer
  • Patrick J. Riss
  • Eva Grill
  • Monika Pischetsrieder
  • Torsten Kuwert
  • Olaf Prante
Original Article



Post-synaptic dopamine D2/3 receptors are reduced in animal models of obesity, and in obese humans, concordant with similar findings in habitual drug users. However, corresponding pre-synaptic changes in brain dopamine are less documented in obesity models. Therefore, we used positron emission tomography (PET) with the dopamine transporter (DAT) ligand N-(3-[18F]fluoropropyl)-2-β-carbomethoxy-3-β-(4′-methylphenyl) tropane ([18F]FP-CMT) to test the hypothesis that DAT availability is attenuated in adult fatty Zucker (FZ) rats versus lean littermates (LZ).


Groups of nine FZ and LZ rats were examined by [18F]FP-CMT PET at approximately 6 weeks and at 6 months of age.


The baseline mean striatal binding potential (BPND) of [18F]FP-CMT did not differ between groups (LZ 2.4; FZ 2.5), although FZ rats already had higher body weight and elevated blood triglycerides, cholesterol, and insulin. At follow-up, a mixed effects multiple regression model showed that the maturation of DAT availability was attenuated in FZ rats, such that the mean BPND in striatum was 17 % lower (LZ 4.0; FZ 3.3; p = 0.01). Body weight was twofold higher in the adult FZ rats, and triglycerides fourfold increased, but glucose remained normal despite doubling of insulin levels.


Maturation of the striatal dopamine innervation is impaired in this model of obesity/hyperlipidaemia without diabetes, implying an acquired trait of reduced dopamine reuptake capacity.

Key words

Dopamine transporters DAT Positron emission tomography Striatum Obesity Zucker rats 



This study is part of the Neurotrition Project, which is supported by the Emerging Fields Initiative (EFI) of the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU). We thank Manuel Geisthoff for expert technical support. For performing the insulin assays, we thank Dr Christof Schöfl and Jürgen Kressel (Division of Endocrinology and Diabetes, Department of Medicine 1, FAU, Erlangen, Germany).

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

11307_2014_811_MOESM1_ESM.pdf (319 kb)
ESM 1 (PDF 318 kb)


  1. 1.
    Zis AP, Fibiger HC (1975) Neuroleptic-induced deficits in food and water regulation—similarities to lateral hypothalamic syndrome. Psychopharmacologia 43:63–68PubMedCrossRefGoogle Scholar
  2. 2.
    Hoch T, Kreitz S, Gaffling S et al (2013) Manganese-enhanced magnetic resonance imaging for mapping of whole brain activity patterns associated with the intake of snack food in ad libitum Fed rats. PLoS One 8:e55354PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Westerink BH, Teisman A, de Vries JB (1994) Increase in dopamine release from the nucleus accumbens in response to feeding: a model to study interactions between drugs and naturally activated dopaminergic neurons in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 349:230–235PubMedCrossRefGoogle Scholar
  4. 4.
    Haltia LT, Rinne JO, Merisaari H et al (2007) Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse 61:748–756PubMedCrossRefGoogle Scholar
  5. 5.
    Haltia LT, Rinne JO, Helin S et al (2008) Effects of intravenous placebo with glucose expectation on human basal ganglia dopaminergic function. Synapse 62:682–688PubMedCrossRefGoogle Scholar
  6. 6.
    Volkow ND, Wang GJ, Fowler JS et al (2002) “Nonhedonic” food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 44:175–180PubMedCrossRefGoogle Scholar
  7. 7.
    Small DM, Jones-Gotman M, Dagher A (2003) Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroimage 19:1709–1715PubMedCrossRefGoogle Scholar
  8. 8.
    Wang GJ, Volkow ND, Thanos PK, Fowler JS (2004) Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review. J Addict Dis 23:39–53PubMedCrossRefGoogle Scholar
  9. 9.
    Tellez LA, Medina S, Han W et al (2013) A gut lipid messenger links excess dietary fat to dopamine deficiency. Science 341:800–802PubMedCrossRefGoogle Scholar
  10. 10.
    Cumming P, Maschauer S, Riss PJ et al (2014) Radiosynthesis and validation of 18F-FP-CMT, a phenyltropane with superior properties for imaging the dopamine transporter in living brain. J Cereb Blood Flow Metab 34:1148–1156PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158PubMedCrossRefGoogle Scholar
  12. 12.
    Cumming P, Rosa-Neto P, Watanabe H et al (2003) Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain. Neuroimage 19:1127–1136PubMedCrossRefGoogle Scholar
  13. 13.
    Bryk AS, Raudenbush SW (1987) Application of hierarchical linear-models to assessing change. Psychol Bull 101:147–158CrossRefGoogle Scholar
  14. 14.
    Rogosa D, Brandt D, Zimowski M (1982) A growth curve approach to the measurement of change. Psychol Bull 92:726–748CrossRefGoogle Scholar
  15. 15.
    Singer JD, Willett JB (2003) Applied longitudinal data analysis: modeling change and event occurrence. Oxford University Press, New YorkCrossRefGoogle Scholar
  16. 16.
    Hume SP, Gunn RN, Jones T (1998) Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur J Nucl Med 25:173–176PubMedCrossRefGoogle Scholar
  17. 17.
    Flores G, Wood GK, Barbeau D et al (1998) Lewis and Fischer rats: a comparison of dopamine transporter and receptors levels. Brain Res 814:34–40PubMedCrossRefGoogle Scholar
  18. 18.
    Hebert MA, Larson GA, Zahniser NR, Gerhardt GA (1999) Age-related reductions in [3H]WIN 35,428 binding to the dopamine transporter in nigrostriatal and mesolimbic brain regions of the Fischer 344 rat. J Pharmacol Exp Ther 288:1334–1339PubMedGoogle Scholar
  19. 19.
    Moll GH, Mehnert C, Wicker M et al (2000) Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Dev Brain Res 119:251–257CrossRefGoogle Scholar
  20. 20.
    Gordon I, Weizman R, Rosenne E, Rehavi M (1995) Developmental and age-related alterations in rat brain presynaptic dopaminergic mechanisms. Dev Brain Res 85:225–228CrossRefGoogle Scholar
  21. 21.
    Volz TJ, Farnsworth SJ, Rowley SD et al (2009) Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse 63:147–151PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Haycock JW, Becker L, Ang L et al (2003) Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 87:574–585PubMedCrossRefGoogle Scholar
  23. 23.
    Cumming P (2011) Absolute abundances and affinity states of dopamine receptors in mammalian brain: a review. Synapse 65:892–909PubMedCrossRefGoogle Scholar
  24. 24.
    Kishimoto Y, Davies WE, Radin NS (1965) Developing rat brain: changes in cholesterol, galactolipids, and the individual fatty acids of gangliosides and glycerophosphatides. J Lipid Res 6:532–536PubMedGoogle Scholar
  25. 25.
    Lemmens HJ, Saidman LJ, Eger EI 2nd, Laster MJ (2008) Obesity modestly affects inhaled anesthetic kinetics in humans. Anesth Analg 107:1864–1870PubMedCrossRefGoogle Scholar
  26. 26.
    Dalley JW, Fryer TD, Brichard L et al (2007) Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315:1267–1270PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Hamdi A, Porter J, Prasad C (1992) Decreased striatal D2 dopamine receptors in obese Zucker rats: changes during aging. Brain Res 589:338–340PubMedCrossRefGoogle Scholar
  28. 28.
    Davis LM, Michaelides M, Cheskin LJ et al (2009) Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. Neuroendocrinology 89:152–162PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Thanos PK, Michaelides M, Piyis YK et al (2008) Food restriction markedly increases dopamine D2 receptor (D2R) in a rat model of obesity as assessed with in-vivo muPET imaging ([11C] raclopride) and in-vitro ([3H] spiperone) autoradiography. Synapse 62:50–61PubMedCrossRefGoogle Scholar
  30. 30.
    Volkow ND, Wang GJ, Telang F et al (2008) Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. Neuroimage 42:1537–1543PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    de Weijer BA, van de Giessen E, van Amelsvoort TA et al (2011) Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. EJNMMI Res 1:37PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Steele KE, Prokopowicz GP, Schweitzer MA et al (2010) Alterations of central dopamine receptors before and after gastric bypass surgery. Obes Surg 20:369–374PubMedCrossRefGoogle Scholar
  33. 33.
    Narayanaswami V, Thompson AC, Cassis LA et al (2013) Diet-induced obesity: dopamine transporter function, impulsivity and motivation. Int J Obes (Lond) 37:1095–1103CrossRefGoogle Scholar
  34. 34.
    South T, Huang XF (2008) High-fat diet exposure increases dopamine D2 receptor and decreases dopamine transporter receptor binding density in the nucleus accumbens and caudate putamen of mice. Neurochem Res 33:598–605PubMedCrossRefGoogle Scholar
  35. 35.
    Cone JJ, Chartoff EH, Potter DN et al (2013) Prolonged high fat diet reduces dopamine reuptake without altering DAT gene expression. PLoS One 8:e58251PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Figlewicz DP, Patterson TA, Johnson LB et al (1998) Dopamine transporter mRNA is increased in the CNS of Zucker fatty (fa/fa) rats. Brain Res Bull 46:199–202PubMedCrossRefGoogle Scholar
  37. 37.
    Thomsen G, Ziebell M, Jensen P et al (2013) No correlation between body mass index and striatal dopamine transporter availability in healthy volunteers using SPECT and [123I] PE2I. Obesity 21:1803–1806PubMedGoogle Scholar
  38. 38.
    van de Giessen E, Hesse S, Caan MWA et al (2013) No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. Neuroimage 64:61–67PubMedCrossRefGoogle Scholar
  39. 39.
    Chen PS, Yang YK, Yeh TL et al (2008) Correlation between body mass index and striatal dopamine transporter availability in healthy volunteers—a SPECT study. Neuroimage 40:275–279PubMedCrossRefGoogle Scholar
  40. 40.
    Berk PD, Zhou SL, Kiang CL et al (1997) Uptake of long chain free fatty acids is selectively up-regulated in adipocytes of Zucker rats with genetic obesity and non-insulin-dependent diabetes mellitus. J Biol Chem 272:8830–8835PubMedCrossRefGoogle Scholar
  41. 41.
    Chan CB, Pederson RA, Buchan AM et al (1985) Gastric inhibitory polypeptide and hyperinsulinemia in the Zucker (fa/fa) rat: a developmental study. Int J Obes 9:137–146PubMedGoogle Scholar
  42. 42.
    Garcia BG, Wei Y, Moron JA et al (2005) Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol 68:102–109PubMedGoogle Scholar
  43. 43.
    Mebel DM, Wong JC, Dong YJ, Borgland SL (2012) Insulin in the ventral tegmental area reduces hedonic feeding and suppresses dopamine concentration via increased reuptake. Eur J Neurosci 36:2336–2346PubMedCrossRefGoogle Scholar
  44. 44.
    Hommel JD, Trinko R, Sears RM et al (2006) Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 51:801–810PubMedCrossRefGoogle Scholar
  45. 45.
    Palacios N, Gao X, McCullough ML et al (2011) Obesity, diabetes, and risk of Parkinson’s disease. Mov Disord 26:2253–2259PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© World Molecular Imaging Society 2014

Authors and Affiliations

  • Paul Cumming
    • 1
  • Simone Maschauer
    • 1
  • Patrick J. Riss
    • 2
  • Eva Grill
    • 3
  • Monika Pischetsrieder
    • 4
  • Torsten Kuwert
    • 1
  • Olaf Prante
    • 1
  1. 1.Department of Nuclear Medicine, Molecular Imaging and RadiochemistryFriedrich-Alexander-Universität Erlangen-Nürnberg (FAU)ErlangenGermany
  2. 2.Kjemisk InstituttUniversitetet i OsloOsloNorway
  3. 3.Institute for Medical Information Processing, Biometry and Epidemiology, and German Center for Vertigo and Balance DisordersLudwig-Maximilians Universität MünchenMunichGermany
  4. 4.Department of Chemistry and Pharmacy, Food Chemistry Division, Emil Fischer CenterFriedrich-Alexander-Universität Erlangen-Nürnberg (FAU)ErlangenGermany

Personalised recommendations